Compare Danaher Corporation (DHR) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs US Bancorp — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while US Bancorp trades at $65.02 (market cap $100.17B). The key difference: Danaher Corporation is the larger of the two by market cap, and US Bancorp pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| DHR | USB | |
|---|---|---|
Market Cap | $145.83B | $100.17B |
Sector | Health | Financials |
52-Week High | $242.05 | $65.02 |
52-Week Low | $161.91 | $45.28 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
U.S. Bancorp (USB) trades at $64.95, up 1.18% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 12.83 and net income margin of 27.61%, while recent quarters have consistently beaten earnings estimates. Positive sentiment is driven by upbeat Q2 2026 results and analyst upgrades, though RSI levels indicate potential overbought conditions near-term.
The outlook remains favorable with a consensus price target of $70.27, implying 8% upside, supported by dividend stability and lending growth. Risks include interest rate sensitivity and insider selling, but institutional accumulation and robust profitability underpin a constructive view for investors seeking value in regional banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
